(Reuters) -The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. Amgen's drug will be marketed under ...
The approval comes with a black-box warning about the risk of serious infections caused by a bacteria called neisseria meningitidis. Amgen's drug will be marketed under the name Bkemv. Biosimilars ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
The drug tarlatamab, or Imdelltra, made by the company Amgen, tripled patients’ life expectancy, giving them a median survival of 14 months after they took the drug. Some 40% of those who got ...
Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of ...